HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David T Curiel Selected Research

AD 5

1/2014Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).
11/2013Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.
5/2012Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
3/2011A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
12/2010Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
6/2010Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David T Curiel Research Topics

Disease

166Neoplasms (Cancer)
02/2021 - 01/2002
57Infections
01/2021 - 01/2002
43Melanoma (Melanoma, Malignant)
01/2016 - 08/2002
25Ovarian Neoplasms (Ovarian Cancer)
01/2021 - 04/2002
17Glioma (Gliomas)
12/2021 - 10/2002
12Prostatic Neoplasms (Prostate Cancer)
02/2017 - 03/2004
12Carcinoma (Carcinomatosis)
06/2010 - 04/2002
10Breast Neoplasms (Breast Cancer)
01/2016 - 01/2005
10Cicatrix (Scar)
01/2016 - 01/2002
7Neoplasm Metastasis (Metastasis)
03/2019 - 07/2003
6Glioblastoma (Glioblastoma Multiforme)
12/2017 - 10/2002
6Adenoviridae Infections (Adenovirus Infections)
01/2015 - 06/2003
6Pancreatic Neoplasms (Pancreatic Cancer)
09/2012 - 10/2003
5Osteosarcoma (Osteogenic Sarcoma)
08/2016 - 02/2003
5Colorectal Neoplasms (Colorectal Cancer)
05/2012 - 09/2002
5Lung Neoplasms (Lung Cancer)
11/2009 - 08/2002
4Communicable Diseases (Infectious Diseases)
08/2021 - 07/2010
4COVID-19
08/2021 - 10/2020
4Renal Cell Carcinoma (Grawitz Tumor)
01/2013 - 05/2009
4Kidney Neoplasms (Kidney Cancer)
06/2011 - 05/2009
3Brain Neoplasms (Brain Tumor)
01/2021 - 04/2006
3Ascites
03/2019 - 04/2002
3Wounds and Injuries (Trauma)
04/2009 - 09/2006
3Mitochondrial Diseases (Mitochondrial Disease)
09/2008 - 12/2007
3Uterine Cervical Neoplasms (Cancer of the Cervix)
11/2004 - 08/2004
2Inflammation (Inflammations)
10/2020 - 11/2013
2Malaria
01/2017 - 01/2016
2Parkinson Disease (Parkinson's Disease)
08/2014 - 09/2010
2Hypoxia (Hypoxemia)
11/2013 - 08/2002
2Hepatocellular Carcinoma (Hepatoma)
04/2013 - 09/2008

Drug/Important Bio-Agent (IBA)

42Proteins (Proteins, Gene)FDA Link
03/2019 - 01/2002
28InterleukinsIBA
08/2014 - 08/2004
28adenovirus receptorIBA
01/2014 - 01/2002
25CytokinesIBA
02/2021 - 07/2003
18VaccinesIBA
08/2021 - 09/2002
15LuciferasesIBA
11/2013 - 11/2002
14Coxsackie and Adenovirus Receptor-Like Membrane ProteinIBA
06/2008 - 03/2002
12SurvivinIBA
01/2021 - 04/2004
11AntigensIBA
07/2018 - 01/2004
11LigandsIBA
01/2017 - 01/2002
11Biological ProductsIBA
01/2014 - 10/2003
11IntegrinsIBA
04/2011 - 03/2002
9Neutralizing AntibodiesIBA
01/2021 - 08/2002
8Pharmaceutical PreparationsIBA
03/2019 - 07/2004
7Interleukin-10 (Interleukin 10)IBA
05/2012 - 06/2008
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2010 - 03/2002
6AD 5IBA
01/2014 - 06/2010
6CeramidesIBA
09/2011 - 05/2009
6Antineoplastic Agents (Antineoplastics)IBA
02/2010 - 08/2002
6Thymidine KinaseIBA
12/2009 - 04/2002
6Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2009 - 10/2003
6ErbB Receptors (EGF Receptor)IBA
06/2008 - 01/2004
5Peptides (Polypeptides)IBA
01/2016 - 01/2002
5Phosphotransferases (Kinase)IBA
04/2010 - 03/2007
5Messenger RNA (mRNA)IBA
03/2008 - 03/2002
5Secretory Leukocyte Peptidase InhibitorIBA
02/2005 - 03/2003
4EpitopesIBA
02/2021 - 03/2005
4Carcinoembryonic AntigenIBA
01/2015 - 09/2002
4Neoplasm Antigens (Tumor Antigens)IBA
01/2012 - 05/2005
4Small Interfering RNA (siRNA)IBA
12/2010 - 11/2007
4Red Fluorescent ProteinIBA
10/2010 - 09/2009
4Therapeutic UsesIBA
12/2006 - 10/2002
4PolylysineIBA
11/2005 - 07/2002
4MidkineIBA
01/2005 - 04/2002
3OsteocalcinIBA
02/2021 - 02/2003
3EnzymesIBA
01/2021 - 12/2010
3AntibodiesIBA
10/2020 - 01/2015
3Cisplatin (Platino)FDA LinkGeneric
03/2019 - 08/2004
3ChemokinesIBA
01/2016 - 06/2004
3ElementsIBA
11/2013 - 10/2003
3CD40 Ligand (CD40L)IBA
09/2011 - 12/2005
3tanespimycin (17AAG)IBA
03/2011 - 01/2008
3Reactive Oxygen Species (Oxygen Radicals)IBA
11/2010 - 03/2007
3Capsid Proteins (Capsid Protein)IBA
04/2010 - 03/2003
3Ganciclovir (Cytovene)FDA LinkGeneric
01/2009 - 04/2002
3Firefly LuciferasesIBA
01/2009 - 11/2004
3CaspasesIBA
06/2008 - 08/2002
3Green Fluorescent ProteinsIBA
10/2006 - 05/2003
3Epidermal Growth Factor (EGF)IBA
11/2004 - 08/2003
2SteroidsIBA
01/2022 - 01/2004
2Viral RNAIBA
10/2020 - 05/2004
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2017 - 11/2013
2MesothelinIBA
03/2016 - 06/2008
2GemcitabineFDA Link
04/2015 - 11/2009
2Somatostatin Receptors (Somatostatin Receptor)IBA
01/2014 - 02/2004
2NF-kappa B (NF-kB)IBA
11/2013 - 07/2003
2Membrane Glycoproteins (Membrane Glycoprotein)IBA
01/2013 - 06/2008
2enhanced green fluorescent proteinIBA
01/2013 - 08/2002
2Gentian Violet (Violet, Crystal)FDA Link
09/2012 - 03/2006
2Phosphates (Orthophosphate)IBA
09/2012 - 04/2009
21,1',6,6',7,7'- hexahydroxy- 3,3'- dimethyl- N5- (2- phenylpropyl)- N5'- (2- phenylpropyl)- 2,2'- binaphthyl- 5,5'- dicarboxamideIBA
05/2012 - 05/2011
2apogossypolIBA
05/2012 - 05/2011
2CalpainIBA
09/2011 - 05/2010

Therapy/Procedure

92Therapeutics
01/2021 - 01/2002
17Drug Therapy (Chemotherapy)
12/2021 - 03/2002
11Immunotherapy
01/2021 - 02/2002
6Injections
02/2010 - 10/2002
5Radiotherapy
03/2009 - 10/2002
4Oncolytic Virotherapy
01/2021 - 08/2003
2Intravenous Administration
04/2013 - 05/2004